7 February 2017 - Roche Canada today announced that Health Canada has approved Gazyva (obinutuzumab) in combination with bendamustine followed by Gazyva monotherapy for the treatment of patients with follicular lymphoma who relapsed after, or are refractory to, a Rituxan (rituximab)-containing regimen.

Each year, an estimated 2,800 Canadians are diagnosed with follicular lymphoma, a slow-growing form of non-Hodgkin's lymphoma. While chemotherapy and targeted treatments such as Rituxan – the current standard of care – have improved survival rates for patients impacted by the disease, follicular lymphoma often recurs.

Read Roche press release